The Evolution of Medical Affairs Central Teams: Shaping Strategic Action and Driving Healthcare Transformation...

The evolving role of Medical Affairs (MA) has positioned this department as a key element in the development and lifecycle management of pharmaceutical products. In response to internal and external assessments, AstraZeneca (AZ) Spain implemented a transformation of its MA central teams through a newly designed Working Model. This model ensures full engagement across the product lifecycle, spanning early access, pre-launch, launch, and post-launch, balancing global strategy with local execution, enhancing cross-functional collaboration, and timely evidence generation. Central to this transformation is the deployment of four coordinated teams: the Early Asset Strategy Team, the Launch Readiness Team, the Core Value Team, and the Brand Team. These teams follow a structured work methodology and coordination model underpinned by dedicated information management processes that streamline communication and knowledge transfer. Training and capability-building programmes were also introduced to strengthen critical functional and leadership competencies. These changes aim to improve product positioning, accelerate market access, and drive value-based healthcare outcomes. The initiative aligns with broader industry trends emphasising early stakeholder engagement, data integration, and patient-centric strategies. By fostering agility, strategic foresight, and internal consistency, the transformation of MA central teams at AZ Spain provides a replicable model for enhancing MA's contribution to product development and healthcare ecosystem innovation. This article builds on our previous publications about the national ecosystem assessment of stakeholder needs, the definition of our MA transformation framework (articulating the strategic roadmap), and the description of the evolution of in-field MA teams in AZ Spain. Here we detail the transformation of the MA central teams and their working model. Future MA evolution will integrate emerging technologies like artificial intelligence (AI) and digital tools, improving stakeholder engagement, evidence generation, and decision making. The transformative potential of AI in anticipating trends and optimising trials will enhance the role of MA in driving innovation and improving patient outcomes.